<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386630</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-CES-2017-01</org_study_id>
    <nct_id>NCT03386630</nct_id>
  </id_info>
  <brief_title>Effects of Analgesics in Cesarean Section Elective</brief_title>
  <acronym>CES</acronym>
  <official_title>The Effects of Sufentanil or Morphine Added to Hyperbaric Bupivacaine in Spinal Anaesthesia for Elective Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two approved treatments for spinal anesthesia will be compared in women undergoing cesarean
      section.

      It is usual to perform cesarean sections using spinal anesthesia with a local anesthetic
      (bupivacaine) plus some opioid, such as sufentanil or morphine. Both have been shown to
      decrease postoperative pain, but we try to check if one brings more benefit than the other.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized clinical trial, without masking techniques, is proposed in pregnant women who are to undergo elective caesarean section by subarachnoid anesthesia with hyperbaric bupivacaine associated with sufentanil or morphine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the time it takes the patients administer a first analgesic bolus of morphine intravenous personally after subarachnoid anesthesia in elective cesarean section.</measure>
    <time_frame>3 days</time_frame>
    <description>To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine plus opioid: sufentanil or morphine, produces a longer time for the patient to administer a first analgesic bolus of intravenous morphine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lower intravenous morphine consumption</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of minor pain verbal scales</measure>
    <time_frame>At 3, 6, 12 and 24 hours after surgery</time_frame>
    <description>The measure is based in EVA (Escala visual analógica del dolor) scale. EVA scale allows to measure the pain intensity that the patient describes with the maximum reproducibility among the observers.
Mild pain if the patient scores the pain as less than 3.
Moderate pain if the assessment is between 4 and 7.
Severe pain if the assessment is equal to or greater than 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beginning of sitting and standing</measure>
    <time_frame>At 48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mother´s side effects with respect to hemodynamic alteration, nausea, vomits, pruritus, tremor, urinary retention, sedation, respiratory depression, headaches, motor deficits, permanent sensory or autonomic deficits.</measure>
    <time_frame>At intraoperative</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Values in the Apgar test</measure>
    <time_frame>At 1 and 5 minutes after birth</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Anesthesia; Functional</condition>
  <arm_group>
    <arm_group_label>Hyperbaric bupivacaine+Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric bupivacaine+morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric bupivacaine+Sufentanil</intervention_name>
    <description>To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)</description>
    <arm_group_label>Hyperbaric bupivacaine+Sufentanil</arm_group_label>
    <other_name>Sufentanil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric bupivacaine+Morphine</intervention_name>
    <description>To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)</description>
    <arm_group_label>Hyperbaric bupivacaine+morphine</arm_group_label>
    <other_name>Morphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of at least 18 years.

          -  Patients at least 36 weeks gestation.

          -  Patients scheduled for non-urgent cesarean section.

          -  Patients classified in the physical state of the American Society of Anesthesiologists
             (ASA) as grade I-II, and without important fetal pathological conditions.

          -  Signature of informed consent that allows them to be part of the study.

        Exclusion Criteria:

          -  Pregnant women who reject the spinal technique.

          -  Patients with contraindication to spinal anesthesia.

          -  Patients with ASA&gt; II classification.

          -  Patients with multiple pregnancy.

          -  Patients with three or more previous cesareans,

          -  Patients with BMI greater than or equal to 40 kg / m2.

          -  Language barrier.

          -  Patients with pre-eclampsia.

          -  Patients with a history of chronic pain.

          -  Patients with a history of psychiatric or drug abuse.

          -  Patients with allergy to any of the drugs used in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The study population will be pregnant women who will undergo elective cesarean section through Subarachnoid anesthesia.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco Javier Arroyo arroyo fernandez, MD</last_name>
    <phone>902 50 50 61</phone>
    <email>fcoarronimo@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María del Mar Benjumea Vargas</last_name>
    <phone>955 040 460</phone>
    <email>gestionensayosclinicos.fps@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital La Línea</name>
      <address>
        <city>Cadiz</city>
        <zip>11300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Javier Arroyo Fernández, MD</last_name>
      <phone>956 02 65 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

